Trial Profile
CPT in combination with thalidomide in refractory/relapsed MM.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Oct 2016
Price :
$35
*
At a glance
- Drugs Aponermin (Primary) ; Thalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 21 May 2012 Actual end date (28 Feb 2011) added as reported by Chinese Clinical Trial Register record.
- 12 Apr 2012 New trial record